Skip to content
type1.science
Phase 1RecruitingNCT06919354

POLARIS: GNTI-122 engineered Tregs in recent-onset T1D

GentiBio phase 1 study of GNTI-122, a one-time autologous engineered regulatory T-cell therapy made from the participant's own blood cells, in adults recently diagnosed with type 1 diabetes.

Primary endpoints

  • Safety and tolerability of GNTI-122 with and without rapamycin

Results so far

No results posted yet.